Novavax, Inc. (NVV1.F) FSX

5.77

-0.074(-1.27%)

Updated at December 23 09:54PM

Currency In EUR

Novavax, Inc.

Address

21 Firstfield Road

Gaithersburg, MD 20878

United States of America

Phone

240 268 2000

Sector

Healthcare

Industry

Biotechnology

Employees

952

First IPO Date

February 01, 2001

Key Executives

NameTitlePayYear Born
John Charles JacobsPresident, Chief Executive Officer & Director1.32M1967
James Patrick KellyExecutive VP, CFO & Treasurer749,9781966
Elaine O'HaraExecutive VP & Chief Strategy Officer844,0321968
Mark CaseyExecutive VP, Chief Legal Officer & Corporate Secretary849,4291963
Henrietta UkwuExecutive VP & Chief Regulatory Officer01967
Ian J. WatkinsExecutive VP & Chief Human Resources Officer01963
Richard CrowleyExecutive VP & COO01957
Troy MorganSenior VP, Deputy General Counsel & Chief Compliance Officer01971
Erika S. TrahanAssociate Director of Investor & Public Relations0N/A
Silvia TaylorExecutive Vice President, Chief Corporate Affairs Officer & Head of Novavax Sweden0N/A

Description

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.